Cycling fibroblast burden

1. Semaglutide decreases cycling fibroblast burden in silico (90th percentile ΔAUC: -0.006).

   “Prolonged (6-month) pre-treatment was detrimental in high-IR phenotypes (90th percentile ΔAUC: -0.006).”

   In silicohigh-IR phenotypes receiving Sofwave6 months

   A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing

   Aesthetic plastic surgery·17 Jun 2026

More on Semaglutide